Epithelial ovarian cancer
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]
Possible genetic alteration in epithelial ovarian cancers | ||
---|---|---|
Protein | Normal function | Result of mutation |
Epidermal growth factor receptor (HER-1)[1][2] |
|
|
Human Epidermal Growth Factor Receptor 2 (HER-2)[1][2] |
|
|
Non-receptor tyrosine kinase Src[3][4] | Involved in regulation of
|
|
CSF-1/fms | ||
ILGF/ILGFR | ||
k-ras | ||
b-raf | ||
TGF-β | ||
myc | ||
Cyclin D/Cdk4/6 | ||
Cyclin E/Cdk2 | ||
Cyclin B/Cdk1 | ||
p16 | ||
p27 (kip-1) | ||
p21 (WAF-1) | ||
NFκB | ||
NOEY(ARHI) | ||
PIP3/Akt | ||
PTEN | ||
p53 | ||
BRCA1 | ||
BRCA2 | ||
MLH1/MSH2 | ||
Fas ligand | ||
HLA-G | ||
hTERT | ||
VEGF/VEGFR | ||
IL-8 | ||
EphA2 | ||
MMPs | ||
αvβ3 | ||
FAK | ||
E-cadherin | ||
References
- ↑ 1.0 1.1 Wee P, Wang Z (May 2017). "Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways". Cancers (Basel). 9 (5). doi:10.3390/cancers9050052. PMC 5447962. PMID 28513565.
- ↑ 2.0 2.1 Iqbal N, Iqbal N (2014). "Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications". Mol Biol Int. 2014: 852748. doi:10.1155/2014/852748. PMC 4170925. PMID 25276427.
- ↑ Zan L, Wu H, Jiang J, Zhao S, Song Y, Teng G, Li H, Jia Y, Zhou M, Zhang X, Qi J, Wang J (July 2011). "Temporal profile of Src, SSeCKS, and angiogenic factors after focal cerebral ischemia: correlations with angiogenesis and cerebral edema". Neurochem. Int. 58 (8): 872–9. doi:10.1016/j.neuint.2011.02.014. PMC 3100427. PMID 21334414.
- ↑ Reinecke JB, Katafiasz D, Naslavsky N, Caplan S (April 2014). "Regulation of Src trafficking and activation by the endocytic regulatory proteins MICAL-L1 and EHD1". J. Cell. Sci. 127 (Pt 8): 1684–98. doi:10.1242/jcs.133892. PMC 3986674. PMID 24481818.